Physician profile
Ran Huo
NPI 1376779371
$4,901.46
in general payments reported to CMS, 2019-2025
24 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $383 · 2021: $753 · 2022: $778 · 2023: $713 · 2024: $963 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,003.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $635.42 | 2019-2025 | |
| Genzyme Corporation | $288.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $263.19 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $239.23 | 2019-2025 | Tremfya |
| Incyte Corporation | $200.66 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $194.84 | 2024-2025 | Sotyktu |
| Ucb, INC. | $149.20 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $125.51 | 2020-2025 | Otezla, Otezla |
| Genentech USA, INC. | $112.11 | 2019-2021 | |
| Lilly USA, LLC | $106.04 | 2019-2024 | Taltz |
| Pfizer INC. | $84.13 | 2019-2025 | |
| Galderma Laboratories, L.P. | $75.95 | 2022-2025 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.56 | 2020-2024 | Jublia, Arazlo |
| Sun Pharmaceutical Industries INC. | $69.50 | 2019-2023 | Odomzo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.83 | 2023-2024 | Spevigo |
| Leo Pharma INC. | $60.98 | 2019-2025 | Spevigo |
| Celgene Corporation | $41.81 | 2019 | |
| Verrica Pharmaceuticals INC. | $24.62 | 2023 | Ycanth |
| Cipher Pharmaceuticals US LLC | $24.12 | 2025 | Natroba, Spinosad |
| Smith+Nephew, INC. | $20.00 | 2022 | |
| Mayne Pharma Commercial LLC | $15.79 | 2025 | |
| Almirall LLC | $15.68 | 2021 | |
| Organon LLC | $12.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ran Huo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.